MBrace Therapeutics

MBrace Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The company utilizes its proprietary SPARTA technology, which leverages in vivo screening to identify antibodies and drug targets that are effective in a complex tumor microenvironment. MBrace’s lead ADC candidate, MBRC-101, uniquely targets the EphA5 receptor tyrosine kinase, which is present in multiple cancers but not in normal tissues. MBRC-101 is currently in a Phase 1 clinical trial evaluating its safety, efficacy, and pharmacokinetic profile in patients with advanced metastatic solid tumors.

MBrace Therapeutics is committed to improving the lives of cancer patients by developing novel treatments for difficult-to-treat cancers. The company has a strong team of experienced drug developers and scientists, and has received significant funding from investors who believe in the potential of its technology and pipeline. With its innovative approach and robust clinical development program, MBrace Therapeutics is well positioned to become a leader in the field of ADC therapy.

MBrace Therapeutics is a clinical-stage oncology company dedicated to improving the lives of cancer patients by developing novel antibody-drug conjugates (ADCs) against solid tumor targets. Their mission is to translate innovative discoveries into transformative therapies for cancer patients by leveraging their proprietary SPARTA technology to identify and target novel antigens. This technology platform overcomes the limitations of traditional antibody discovery methods, allowing MBrace to develop first-in-class ADC therapeutics with the potential to treat a variety of difficult-to-treat cancers.

MBrace Therapeutics fosters a collaborative and driven culture where experienced individuals from diverse backgrounds come together to advance cancer treatment. The company emphasizes the importance of teamwork, innovation, and dedication to patients, with each team member having been personally impacted by cancer. This shared experience fuels their commitment to translating research into effective and novel therapies, creating a supportive environment where creativity and collaboration thrive.